(Q33780878)

29 July 2017

1 reference

title

Beyond lipids - the role of the endothelium in coronary artery disease (English)

1 reference

29 July 2017

0 references

coronary artery disease

1 reference

Aengevaeren WR

1

1 reference

29 July 2017

1 September 1999

1 reference

29 July 2017

1 reference

29 July 2017

147 Suppl 1

1 reference

29 July 2017

S11-6

1 reference

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Coronary plaque disruption.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Statins do more than just lower cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Endothelial dysfunction: does it matter? Is it reversible?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Is NO an endogenous antiatherogenic molecule?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Close relation of endothelial function in the human coronary and peripheral circulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Homocysteine and vascular dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Psychosocial factors impair vascular responses of coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Mechanisms modifying atherosclerotic disease - from lipids to vascular biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900250-6

10.1016/S0021-9150(99)00250-6

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10575057